Gene editing company Seamless Therapeutics has raised EUR 11.8 million (USD 12.5 million) in a seed financing round co-led by Wellington Partners and Forbion. The raised funds included non-dilutive financing from BMBF GO-Bio, an initiative by the German government.
The Germany-based company follows a gene-editing approach that develops designer recombinases: programmable enzymes that are reportedly capable of editing substantial portions of genes, unlike natural recombinases that work on very specific target sequences. The company plans to use the funding to further develop its technology platform and expand its presence in the EU and US.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.